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Advances in technology and continual commercial application of this 
technology to animal agriculture has enabled producers to deliver large 
quantities of animal food products to the consuming public. The steady 
supply of these nutritious animal products has contributed significantly 
to enhancing the quality of life. Whereas in the early 1900’s many of the 
health problems were related to nutritional deficiencies, today many of 
the health problems are associated with the over-consumption of calories, 
saturated fatty acids and cholesterol.
Whereas research in the past has focused primarily on methods to 
maximize productivity of food-producing animals to lower cost of pro-
duction for the producer and cost of food products for the consumer, fu-
ture research efforts will need to focus more on the development of tech-
nologies that will improve product quality and assure food safety. Recent 
advances in biotechnology such as the use of recombinant DNA technol-
ogy to supply large quantities of polypeptide hormones such as soma-
totropin (ST) appear to hold considerable promise towards satisfying 
these changing demands for animal food products.
To ensure eventual consumer acceptance of these new technologies it 
will be critical to demonstrate that the technologies will: 1 - be cost effec-
tive, 2 - enhance nutritional value, 3 - improve product quality and 4 - be 
safe for human consumption, the target animals and the environment. 
Somatotropin is a polypeptide hormone secreted from the anterior pitu-
itary that exerts control over numerous diverse metabolic processes. Al-
though the exact modes of action for ST have yet to be fully elucidated, 
treatment of growing animals with ST has been shown to increase muscle 
growth and reduce adipose tissue stores. Somatotropin’s actions on 
muscle growth are mediated indirectly via IGF-I to increase cellular pro-
liferation and to increase whole-animal protein synthesis. The anabolic 
actions of ST on muscle and bone tissue, combined with the effects of ST 
on metabolism to redirect nutrient utilization, results in leaner tissue 
growth in meat animals.
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RESEARCH DEVELOPMENTS LEADING TO USE OF RECOMBINANT ST
While the technology used to produce recombinant ST is relatively new, 
the research which led to the idea of using ST as an anabolic agent to en-
hance animal productivity is not. Studies conducted in the 1930s using 
crude preparations of pituitary ST in rats were the first to provide evi-
dence to demonstrate the positive effect of ST on growth.
Recombinant DNA is a term which describes the splicing together or re-
combining of two or more pieces of DNA. The recombinant DNA tech-
niques used to produce recombinant BST involves: the cloning of DNA 
(cDNA) from BST mRNA, the recombining of the BST cDNA with bacte-
rial plasmid DNA and re-insertion of the “hybrid” DNA into Escherichia 
Coli bacteria for eventual expression of recombinant BST. The recombi-
nant bacteria are grown in large numbers in typical fermentation vats, and 
the recombinant BST product extracted and purified. These same proce-
dures are currently being used to produce human somatotropin and insu-
lin for the treatment of dwarfism and diabetes mellitus, respectively.
Of the four recombinant BST products that have been produced by U.S. 
pharmaceutical companies and submitted for FDA approval for use in lac- 
tating cows, one is identical in amino acid sequence to endogenous BST, 
while the other three differ only slightly at the NH2-terminus end of the 
protein. Recombinant BST is immunologically indistinguishable from en-
dogenous BST using standard radioimmunoassay procedures.
The first experiment to be conducted with recombinant BST was a 
short-term study with lactating dairy cows which demonstrated that en-
dogenous BST and recombinant BST were similar in increasing milk 
yields. The first experimental application of the use of recombinant ST to 
enhance growth was conducted with pigs.
COST-EFFECTIVENESS OF RECOMBINANT BST
Assuming recombinant BST were to be approved, the eventual adoption 
of recombinant BST by the beef industry and its cost effectiveness to the 
consumer will, among other things, be dependent upon: 1 - recombinant 
BST’s ability to enhance growth performance and feed efficiency, i - the 
ability of recombinant BST to enhance lean tissue growth, 3 - consumer 
acceptance of leaner beef, 4-market value of leaner beef and 5-cost and 
delivery of recombinant BST.
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The efficacy of recombinant BST for use as an anabolic agent in cattle to 
enhance the production of lean beef can not be fully accessed due to the 
limited amount of research that has been conducted with beef cattle to 
date.
An excellent 1989 review of the studies conducted through 1988 on the 
effects of BST on productivity in ruminants. Results of nine longer term 
trials (> 100 doses of BST treatment) concluded with cattle, indicate that 
BST treatment increased growth rates by approximately 12 percent with 
the range of responses being from 3 percent to 25 percent
EFFECT OF RECOMBINANT BST ON THE NUTRITIONAL 
VALUE OF BEEF PRODUCTS
Although the growth responses in cattle to recombinant BST have been 
variable, most studies have shown that BST is effective at increasing the 
lean:fat ratio in the carcass. In a recent study recombinant BST provided 
for 112 days increased daily protein gain by 16 percent and daily fat gain 
also tended to be lower (20 percent) in BST-treated steers. In other recent 
work, BST reduced the percent fat of the 9-10-11 rib section (indicator cut 
of carcass composition) by 13.4,21.2 and 54.4 percent with increasing dos-
age of BST. Recombinant BST in our studies has also been shown to be ef-
fective in growing beef heifers, where 9-10-11 rib sections from BST treated 
heifers contained more protein (16.3 vs 18.3 percent) and less fat (26.0 vs 
16.5 percent). Earlier research indicated that carcass leanness was in-
creased by both BST and estradiol and that the responses were additive 
suggesting that the mode of actions for these anabolic agents may be inde-
pendent. Recent research also suggests that the anabolic response to BST 
is very much dependent upon dietary protein and energy levels.
EFFECT OF RECOMBINANT BST ON THE SAFETY OF BEEF PRODUCTS
Since 1985, pharmaceutical companies seeking approval for the use of re-
combinant BST in lactating dairy cows have had FDA authorization to 
market meat and milk from BST-treated cows. This decision was based on 
their evaluation of extensive toxicological data and review of scientific lit-
erature concerning BST. As a result of consumer concern and due to gen-
eral misunderstanding of human food safety of BST, FDA in an unprec-
edented action, released results of experimental data that had been sub-
mitted to the FDA by the pharmaceutical companies seeking recombinant
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BST approval. The results of these studies were recently published and 
provide an excellent review of pertinent scientific studies which were used 
as the basis for the decision to authorize zero day withdrawal for the con-
sumption of milk and meat from recombinant BST-treated cows.
For years it has been known that pituitary BST is ineffective when ad-
ministered to humans. Although pituitary derived human ST and BST 
both have 191 amino acids, there is approximately a 35 percent difference 
in their amino acid sequence. The amino acid sequence of recombinant 
BST products and pituitary BST are either identical or differ by only a few 
amino acids at the NH2 terminus. Because BST is a protein, it will be de-
graded in the gastrointestinal tract just like any other protein. The prod-
uct of protein digestion (amino acids) generally enter the blood circula-
tion almost entirely as free amino acids. In order to obtain authorization 
for a zero day withdrawal for the marketing of milk and meat from cows 
treated with BST, each pharmaceutical company seeking recombinant 
FDA approval had to conduct studies demonstrating the oral inactivity of 
their individual recombinant BST products.
INSULIN-LIKE GROWTH FACTOR I (iGF-l)
Another concern that has been raised with regards to potential harmful ef-
fects due to ingestion of BST-treated milk or meat involves IGF-I. Indeed, 
IGF-I levels are regulated by ST and elevated levels of IGF-I have been 
found in plasma, milk and meat of bST treated cows, and there exists 100 
percent homology between bovine IGF-I and human IGF-I (identical 
amino acid sequences). However, these concerns have no scientific basis. 
First IGF-I, like ST and all proteins, will be digested to amino acids. Sec-
ondly, IGF-I levels in human breast milk have been shown to be seven to 
eight ng per ml and 19 ng per ml at six to eight week postpartum. These 
levels of IGF-I are much higher than IGF-I levels that have been found in 
milk obtained from cows treated with recombinant BST. Although pas-
teurization of milk will not destroy IGF-I levels, the heating process that 
milk is subjected to in the preparation of infant formula denatures all but 
approximately one tenth of the IGF-I present.
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